Nonscarring Alopecias



For most people, hair is an important part of how they look and feel about themselves. In fact, it can be an important part of one’s identity overall. Some people take their hair for granted until they start to lose it. Alopecia can be an emotionally devastating condition for patients regardless of its severity. Decrease in quality of life has been documented for many different forms of alopecia. Most dermatologists know this intuitively from their own experience in treating these patients who may be unhappy about or even distraught by their condition. The diagnosis of a nonscarring alopecia allows us to offer hope to these patients. The preservation of the hair follicle that is characteristic of these conditions means that there is the possibility of, and in some instances, an excellent chance of regrowth.


Hair Loss Alopecia Areata Impulse Control Disorder Androgenetic Alopecia Scalp Cool 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Reid EE, Haley AC, Borovicka JH, Rademaker A, West DP, Colavincenzo M, Wickless H. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol. 2011;66(3):e97–102.PubMedCrossRefGoogle Scholar
  2. 2.
    Dubois M, Baumstarck-Barrau K, Gaudy-Marqueste C, Richard MA, Loundou A, Auquier P, Grob JJ. Quality of life in alopecia areata: a study of 60 cases. J Invest Dermatol. 2010;130(12):2830–3.PubMedCrossRefGoogle Scholar
  3. 3.
    Porter CE, Diridollou S, Holloway BV. Holloway. Int J Dermatol. 2005;44 Suppl 1:4–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Porter CE, Dixon F, Khine CC, Pistorio B, Bryant H, de la Mettrie R. The behavior of hair from different countries. J Cosmet Sci. 2009;60(2):97–109.PubMedGoogle Scholar
  5. 5.
    Loussouarn G. African hair growth parameters. Br J Dermatol. 2001;145(2):294–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Grubow L, Morris E. The imperative relevance of ethnic hair care. GCI Magazine. 2010.Google Scholar
  7. 7.
    Khumalo NP, Pillay K, Ngwanya RM. Acute ‘relaxer’-associated scarring alopecia: a report of five cases. Br J Dermatol. 2007;156(6):1394–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Miller JJ. Relaxer-induced alopecia. Am J Contact Dermat. 2001;12(4):238–9.PubMedGoogle Scholar
  9. 9.
    Shah SK, Alexis AF. Central centrifugal cicatricial alopecia: retrospective chart review. J Cutan Med Surg. 2010;14(5):212–22.PubMedGoogle Scholar
  10. 10.
    Gathers RC, Jankowski M, Eide M, Lim HW. Hair grooming practices and central centrifugal cicatricial alopecia. J Am Acad Dermatol. 2009;60(4):574–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Khumalo NP, Ngwanya RM. Traction alopecia: 2% topical minoxidil shows promise. Report of two cases. J Eur Acad Dermatol Venereol. 2007;21(3):433–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Hillmer AM, Brockschmidt FF, Hanneken S, Eigelshoven S, Steffens M, Flaquer A, Herms S, Becker T, Kortüm AK, Nyholt DR, Zhao ZZ, Montgomery GW, Martin NG, Mühleisen TW, Alblas MA, Moebus S, Jöckel KH, Bröcker-Preuss M, Erbel R, Reinartz R, Betz RC, Cichon S, Propping P, Baur MP, Wienker TF, Kruse R, Nöthen MM. Susceptibility variants for male-pattern baldness on chromosome 20p11. Nat Genet. 2008;40(11):1279–81.PubMedCrossRefGoogle Scholar
  13. 13.
    Hillmer AM, Flaquer A, Hanneken S, et al. Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. Am J Hum Genet. 2008;82(3):737–43.PubMedCrossRefGoogle Scholar
  14. 14.
    Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY, Ro BI, Cho HK, Sim WY, Lew BL, Lee WS, Park HY, Hong SP, Ji JH. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Elizabeth CW Hughes, MD; Chief Editor: Dirk M Elston, MD. Telogen effluvium.
  16. 16.
    Yun SJ, Kim SJ. Hair loss pattern due to chemotherapy-induced anagen effluvium: a cross-sectional observation. Dermatology. 2007;215(1):36–40.PubMedCrossRefGoogle Scholar
  17. 17.
    Palamaras I, Misciali C, Vincenzi C, Robles WS, Tosti A. Permanent chemotherapy-induced alopecia: a review. J Am Acad Dermatol. 2011;64(3):604–6. Review.PubMedCrossRefGoogle Scholar
  18. 18.
    Trüeb RM. Chemotherapy-induced alopecia. Semin Cutan Med Surg. 2009;28(1):11–4. Review.PubMedCrossRefGoogle Scholar
  19. 19.
    Petukhova L, Cabral RM, Mackay-Wiggan J, Clynes R, Christiano AM. The genetics of alopecia areata: what’s new and how will it help our patients? Dermatol Ther. 2011;24(3): 326–36.PubMedCrossRefGoogle Scholar
  20. 20.
    Ucak H, Kandi B, Cicek D, Halisdemir N, Dertlıoğlu SB. The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata. J Dermatol Treat. 2011. Epub ahead of printGoogle Scholar
  21. 21.
    Vila TO, Camacho Martinez FM. Bimatoprost in the treatment of eyelash universalis alopecia areata. Int J Trichol. 2010;2(2):86–8.CrossRefGoogle Scholar
  22. 22.
    American Psychiatric Association. DSM-IV: Diagnostic & Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000. p. 674–7.Google Scholar
  23. 23.
    Phillips, KA. Report of the DSM-V Anxiety, obsessive-compulsive spectrum, posttraumatic, and dissociative disorders work group. Apr 2009 available at
  24. 24.
    Odlaug BL, Grant JE. Impulse-control disorders in a college sample: results from the self-administered Minnesota Impulse Disorders Interview (MIDI). Prim Care Companion J Clin Psychiatry. 2010;12(2). pii: PCC.09m00842Google Scholar
  25. 25.
    Mausueto CS, Thomas AM, Brice AL. Hair pulling and its affective correlates in an African American university sample. J Anxiety Disord. 2007;21(4):590–9.CrossRefGoogle Scholar
  26. 26.
    White MP, Koran LM. Open-label trial of aripiprazole in the treatment of trichotillomania. J Clin Psychopharmacol. 2011;31(4):503–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Grant JE, Odlaug BL, Chamberlain SR, Kim SW. Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot study. Psychopharmacology (Berl). 2011;218(3):439–502.CrossRefGoogle Scholar
  28. 28.
    Bi MY, Cohen PR, Robinson FW, Gray JM. Alopecia syphilitica-report of a patient with secondary syphilis presenting as moth-eaten alopecia and a review of its common mimickers. Dermatol Online J. 2009;15(10):6.PubMedGoogle Scholar
  29. 29.
    CDC Trends in Sexually Transmitted Diseases in the United States: 2009 National Data for Gonorrhea, Chlamydia and Syphilis available at
  30. 30.
    Jordaan HF, Louw M. The moth-eaten alopecia of secondary syphilis. A histopathological study of 12 patients. Am J Dermatopathol. 1995;17(2):158–62.PubMedCrossRefGoogle Scholar
  31. 31.
    Lee JY, Hsu ML. Alopecia syphilitica, a simulator of alopecia areata: histopathology and ­differential diagnosis. J Cutan Pathol. 1991;18(2):87–92.PubMedCrossRefGoogle Scholar
  32. 32.
    Nam-Cha SH, Guhl G, Fernández-Peña P, Fraga J. Alopecia syphilitica with detection of Treponema pallidum in the hair follicle. J Cutan Pathol. 2007;34 Suppl 1:37–40.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Millenium Park DermatologyChicagoUSA

Personalised recommendations